Last reviewed · How we verify
Acetylsalicylic Acid + clopidogrel
This combination inhibits platelet aggregation through two complementary pathways: acetylsalicylic acid irreversibly inhibits cyclooxygenase to block thromboxane A2 production, while clopidogrel blocks the P2Y12 adenosine diphosphate receptor.
This combination inhibits platelet aggregation through two complementary pathways: acetylsalicylic acid irreversibly inhibits cyclooxygenase to block thromboxane A2 production, while clopidogrel blocks the P2Y12 adenosine diphosphate receptor. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-percutaneous coronary intervention, Stroke prevention in patients with acute ischemic stroke or transient ischemic attack.
At a glance
| Generic name | Acetylsalicylic Acid + clopidogrel |
|---|---|
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Drug class | Dual antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Acetylsalicylic acid (aspirin) prevents platelet activation by irreversibly acetylating cyclooxygenase-1, reducing thromboxane A2 synthesis. Clopidogrel is a thienopyridine that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing platelet aggregation through a different mechanism. Together, they provide dual antiplatelet therapy with synergistic effects to prevent thrombotic events.
Approved indications
- Acute coronary syndrome
- Secondary prevention of cardiovascular events post-percutaneous coronary intervention
- Stroke prevention in patients with acute ischemic stroke or transient ischemic attack
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: